Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Patents on Biotechnology
  4. Volume 19, Issue 2
  5. Article
  • ISSN: 1872-2083
  • E-ISSN: 2212-4012

Abstract

Introduction/Objective

During the 1150 days of COVID-19 pandemic there were great efforts to develop efficient treatments for the disease. After this long time, some drugs emerged as treatment for COVID-19. Some of them are new drugs, most of them, known drugs. These developments were triggered by information already available in patent documents. Pharmaceutical companies, therefore, rushed to conduct drugs evaluations and trials in order to deliver to the world a reasonable treatment that could reach the majority of its population. However, it is not immediately clear how companies operated to reach their goals. The ability of open innovation to achieve results assertively and faster than closed innovation strategies is questioned and therefore, it is questioned whether pharmaceutical companies use open innovation to face COVID-19.

Methods

In this work, data available on patent databases were mined to inform about the scientific and technological panorama of selected drugs tested for COVID-19 treatment and to understand the perspectives of such developments during the pandemic.

Results

This study evidenced that most treatments were based on known drugs, that some of the initially promising drugs were abandoned during the pandemic, and that it was able to inform if open innovation and collaborations were explored strategies.

Conclusion

This study evidenced that the developments during COVID-19 were not based on open innovation by revealing a patent race towards the treatment development, but with practically no collaborations or information exchange between companies, universities, and research facilities.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/biot/10.2174/0118722083303431240528041945
2024-06-19
2025-04-24

  • From This Site

    /content/journals/biot/10.2174/0118722083303431240528041945
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HolderJ. Tracking Coronavirus Vaccinations Around the World.2023Available from: https://www. nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html (Accessed on: Jan 8, 2024).
  2. FrancoS.D. AlfieriA. PetrouS. Current status of COVID-19 treatment: An opinion review.World J. Virol.202093273710.5501/wjv.v9.i3.2733024717
     [Google Scholar]
  3. RosenA. More Americans Could Benefit from Paxlovid for COVID Infection Paxlovid is “A tremendous tool that's completely underutilized”.2024Available from: https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid (Accessed on: Jan 25, 2024).
  4. U.S. Food and Drug AdministrationKnow Your Treatment Options for COVID-19.2023Available from: https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19 (Accessed on: Dec. 12, 2023).
     [Google Scholar]
  5. BrownD.G. WobstH.J. KapoorA. KennaL.A. SouthallN. Clinical development times for innovative drugs.Nat. Rev. Drug Discov.2022211179379410.1038/d41573‑021‑00190‑934759309
     [Google Scholar]
  6. DiMasiJ.A. GrabowskiH.G. HansenR.W. Innovation in the pharmaceutical industry: New estimates of R&D costs.J. Health Econ.201647203310.1016/j.jhealeco.2016.01.01226928437
     [Google Scholar]
  7. KummarS. KindersR. RubinsteinL. Compressing drug development timelines in oncology using phase ‘0’ trials.Nat. Rev. Cancer20077213113910.1038/nrc206617251919
     [Google Scholar]
  8. BuiN.Q. KummarS. Evolution of early phase clinical trials in oncology.J. Mol. Med.2018961313810.1007/s00109‑017‑1612‑729177698
     [Google Scholar]
  9. DahlbergS.E. ShapiroG.I. ClarkJ.W. JohnsonB.E. Evaluation of statistical designs in phase I expansion cohorts: The Dana-Farber/Harvard Cancer Center experience.J. Natl. Cancer Inst.20141067dju16310.1093/jnci/dju16324963024
     [Google Scholar]
  10. Le TourneauC. DelordJ.P. GonçalvesA. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.Lancet Oncol.201516131324133410.1016/S1470‑2045(15)00188‑626342236
     [Google Scholar]
  11. GadiyaY. GribbonP. ApitiusH.M. ZalianiA. Pharmaceutical patent landscaping: A novel approach to understand patents from the drug discovery perspective.Artificial Intellig Life Sci2023310006910.1016/j.ailsci.2023.100069
     [Google Scholar]
  12. PanagopoulosA. Closed Vs Open Innovation. In: Palgrave encycl strat manag.Springer20161410.1057/978‑1‑349‑94848‑2_336‑1
     [Google Scholar]
  13. SchuhmacherA. GassmannO. BieniokD. HinderM. HartlD. Open innovation: A paradigm shift in pharma R&D?Drug Discov. Today20222792395240510.1016/j.drudis.2022.05.01835643258
     [Google Scholar]
  14. JungH. HwangJ. KimE. How to leverage the impact of firm-specific uncertainty on innovation performance? Moderating effects of alliance stage and partner type in the pharmaceutical industry.J. Eng. Technol. Manage.20237010178110.1016/j.jengtecman.2023.101781
     [Google Scholar]
  15. BurkiT. Pharma blockchains AI for drug development.Lancet201939310189238210.1016/S0140‑6736(19)31401‑131204669
     [Google Scholar]
  16. BianchiniS. MüllerM. PelletierP. Artificial intelligence in science: An emerging general method of invention.Res. Policy2022511010460410.1016/j.respol.2022.104604
     [Google Scholar]
  17. MishraR. ChaudharyK. MishraI. AI in Health Science: A Perspective.Curr. Pharm. Biotechnol.20232491149116310.2174/138920102366622092914522036177622
     [Google Scholar]
  18. MishraI. GuptaK. MishraR. ChaudharyK. SharmaV. An exploration of organoid technology: Present advancements, applications, and obstacles.Curr. Pharm. Biotechnol.20242581000102010.2174/0113892010273024230925075231
     [Google Scholar]
  19. MishraR. ChaudharyK. MishraI. Weapons and Strategies against COVID-19: A perspective.Curr. Pharm. Biotechnol.202325214415810.2174/138920102466623052516143237231727
     [Google Scholar]
  20. AbadiM.H.H.E. GhasemlouA. BayaniF. AI-driven covalent drug design strategies targeting main protease (mpro) against SARS-CoV-2: Structural insights and molecular mechanisms. In: Biomol Struct Dyn.National Library of Medicine2024230876910.1080/07391102.2024.2308769
     [Google Scholar]
  21. VoraL.K. GholapA.D. JethaK. ThakurR.R.S. SolankiH.K. ChavdaV.P. Artificial intelligence in pharmaceutical technology and drug delivery design.Pharmaceutics2023157191610.3390/pharmaceutics1507191637514102
     [Google Scholar]
  22. SahuA. MishraJ. KushwahaN. Artificial intelligence (AI) in drugs and pharmaceuticals.Comb. Chem. High Throughput Screen.202225111818183710.2174/138620732566621120715394334875986
     [Google Scholar]
  23. BlockJ. COVID-19 puts spotlight on artificial intelligence: Pandemic amplifies the power of AI to generate actionable information.GEN Edge20202114915510.1089/genedge.2.1.28
     [Google Scholar]
  24. RathiS. MajumdarA. ChatterjeeC. Did the COVID-19 pandemic propel usage of AI in pharmaceutical innovation? New evidence from patenting data.Technol. Forecast. Soc. Change202419812294010.1016/j.techfore.2023.122940
     [Google Scholar]
  25. BoutillierS. LapercheB. LebertD. MrizakE.S. A systemic analysis of the technological trajectory at company level based on patent data: The case of Sanofi’s vaccine technology.Technovation202312410274610.1016/j.technovation.2023.102746
     [Google Scholar]
  26. ChanH.C.S. ShanH. DahounT. VogelH. YuanS. Advancing drug discovery via artificial intelligence.Trends Pharmacol. Sci.201940859260410.1016/j.tips.2019.06.00431320117
     [Google Scholar]
  27. StevensM.P. PatelP.K. NoriP. Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck.Infect. Control Hosp. Epidemiol.202041674474510.1017/ice.2020.6932167442
     [Google Scholar]
  28. AlonsoA.G. PadullésA. RombautsA. Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern.Infect. Control Hosp. Epidemiol.202041111371137210.1017/ice.2020.38132729437
     [Google Scholar]
  29. National Library of Medicine – National Center for Biotechnology informationUnited States of America Government.Available from: https://ClinicalTrials. gov (Accessed on: June 6, 2023).
     [Google Scholar]
  30. World Intellectual Property Organization Patentscope database.2024Available from: https://patentscope. wipo.int/search/en/search.jsf
  31. Espacenet Patent Search2024Available from: https://worldwide.espacenet.com (Accessed on: Feb 1, 2024).
  32. HalfordB. How Pfizer scientists transformed an old drug lead into a COVID-19 antiviral.Behind the scenes of the medicinal chemistry campaign that led to the pill Paxlovid.2022Available from: https://cen. acs.org/pharmaceuticals/drug-discovery/How-Pfizer-scientists-transformed-an-old-drug-lead-into-a-COVID-19-antiviral/100/i3 (Accessed on: Jan 14, 2022).
     [Google Scholar]
  33. (aPfizer to Supply UNICEF up to 4 Million treatment courses of Novel COVID-19 oral treatment for lowand middle-income countries.Pfizer press release.2022Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-supplyunicef-4-million-treatment-courses-novel (Accessed on: March 22, 2022).
     [Google Scholar]
  34. (bPfizer Press release. Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries.2022Available from: https://www.businesswire. com/news/home/20220322005262/en/ (Accessed on: March 22, 2022).
  35. Institute of applied economic research IPEAAvailable from: https://www.ipea.gov.br/cartadeconjuntura/index.php/tag/massa-salarial/#:~:text=Estimativas%20mensais%20mostram%20que%20o,2022%20(R%24%202.929)
  36. Hetero signs licensing agreement with Gilead Sciences, Inc. for manufacturing and distribution of "remdesivir" for COVID-19 in 127 countries, including India. 2020Available from: https://www. prnewswire.com/news-releases/a-hetero-assina-contrato-de-licenciamento-com-a-gilead-sciences-inc-para-a-fabricacao-e-distribuicao-de-remdesivir-para-a-COVID-19-em-127-paises-inclusive-a-india-889819548.html (Accessed on: May 13, 2020).
  37. SenadoA. Senate approves possibility of compulsory licensing of anti-covid vaccine patents.2021Available from: https://www12.senado.leg.br/noticias/materias/2021/04/29/senado-aprova-possibilidade-delicenca-compulsoria-de-patentes-de-vacinas-anticovid
    [Google Scholar]
  38. de AlmeidaETDM CordeiroD PaesT MartinsT Relevance of regional specificities of intellectual property regulations for pharmaceutical industries: Brazilian law changes that immediately affected crucial US-pharmaceutical patents with correspondents in Brazil. 2023Available from: https://esmed.org/MRA/mra/article/view/3830 (Accessed on: Nov 27, 2023).10.18103/mra.v11i6.3830
     [Google Scholar]
  39. StevensP. SchultzM. Building a predictable, stable patent system.2022Available from: https://geneva-network.com/wp-content/uploads/2022/06/2022-Brazil-patent-examination.pdf (Accessed on: Jun 20, 2022).
     [Google Scholar]
  40. SzymcczakK. OshaB. Patent Applicant pendency in various countries: Part 1.2022Available from: https://www.obwb.com/newsletter/patent-applicant-pendency-in-various-countries-part-1 (Accessed on: August 31, 2022).
  41. WIPO IP Statistics. 2022. Available from: https://www.wipo.int/ipstats/en/statistics/country_profile/profile.jsp?code=BR
  42. Action plan of the National Intellectual Property Strategy-ENPI-foresees the granting of patents in 3 years until.2025Available from: https://www. gov.br/inpi/pt-br/central-de-conteudo/noticias/plano-de-acao-da-enpi-preve-concessao-de-patentes-em-3-anos-ate-2025#:~:text=Entre%20elas%2C%20medidas%20de%20promo
  43. GIPI/MDIC RESOLUTIONApproves the 2023- 2025 Action Plan of the National Intellectual Property Strategy. 2023Available from: https://www.in.gov.br/web/dou/-/resolucao-gipi/mdic-n-8-de-18-deoutrubro-de-2023-518452014 (Accessed on: Oct 18, 2023).
     [Google Scholar]
  44. Portaria INPI DIRPA nº 1/21. 2021. Available from: https://www.gov.br/inpi/pt-br/servicos/patentes/legislacao/legislacao/PortariaINPID-IRPA12021_PlanodeCombateaoBacklogatualizacao_PA12021_PlanodeCombateaoBacklogatualizacao_01022021.pdf
  45. LewnardJ.A. McLaughlinJ.M. MaldenD. Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: A cohort study in a large US health-care system.Lancet Infect. Dis.202323780681510.1016/S1473‑3099(23)00118‑436933565
     [Google Scholar]
  46. SouzaK.M. CarrascoG. CortésR.R. Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.PLoS One20231810e028400610.1371/journal.pone.028400637824507
     [Google Scholar]
  47. NIH COVID-19 treatment guidelines.Janus Kinase Inhibitors.Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/janus-kinase-inhibitors/ (Accessed on: Oct 10, 2023).
     [Google Scholar]
  48. Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19.Available from: https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovidstudy-ruxolitinib-hospitalized-patients-COVID-19 (Accessed on: Dec 14, 2020).
  49. WIPO Patent Landscape Report: COVID-19-related vaccines and therapeutics.Preliminary insights on related patenting activity during the pandemic2022Available from: https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-andtherapeutics.pdf 10.34667/tind.45030
     [Google Scholar]
  50. Ministry of Health, Brazilian Federal GovernmentUnified Health System. Structure, Principles and How It Works.Available from: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/s/sus
    [Google Scholar]
  51. Technical informationDirect-acting antivirals for treatment of hepatitis C: Risk of reactivation of hepatitis B.Available from: https://antigo.anvisa.gov.br/informacoes-tecnicas13?p_p_id=101_INSTANCE_ R6VaZWsQDDzS&p_p_col_id=column- 1&p_p_col_pos=1&p_p_col_count=2&_101_INSTA NCE_R6VaZWsQDDzS_groupId=33868&_101_INSTANCE_R6VaZWsQDDzS_urlTitle=risco-dereativacao- da-hepatite-b-em-pacientes-emtratamento- da-hepatite-c-comdda&_ 101_INSTANCE_R6VaZWsQDDzS_struts_ac tion=%2Fasset_publisher%2Fview_content&_101_INSTANCE_R6VaZWsQDDzS_assetEntryId=308666 7&_101_INSTANCE_R6VaZWsQDDzS_type=content#:~:text=Em%202015%2C%20A%20Anvisa%20re gistrou,dasabuvir%20(Viekira%20Pak%C2%AE)
    [Google Scholar]
  52. R7Medicine for hepatitis C can be used to treat COVID-19, study indicates.Available from: https://noticias.r7.com/saude/remedio-para-hepatite-c-pode-servir-para-tratar-a-COVID-19-indica-estudo-28062022 (Accessed on: Dec 14, 2020).
     [Google Scholar]
  53. Rules rights and obligations referring to Industrial property.Available from: https://www.planalto. gov.br/ccivil_03/leis/l9279.htm (Accessed on: May 14, 1996).
  54. Ministry of HealthNational Health Council. Court annuls granted patent and Fiocruz can resume producing generics against hepatitis C. Available from: https://conselho.saude.gov.br/ultimas-noticias-cns/116-justica-anula-patente-concedida-e-fiocruz-pode-voltar-a-produzir-generico-contra-hepatite-c (Accessed on: Sep 28, 2018).
     [Google Scholar]
  55. JunqueiraD. Why Brazil pays up to R$1,400 formedicine that costs R$34.Available from: https://noticias.uol.com.br/cotidiano/ultimas-noticias/reporter-brasil/2019/11/08/remedio-hepatite-csofosbuvir-preco.htm#:~:text=O%20rem%C3%A9dio%2C%20que%20cura%20a,no%20Brasil%20e%20n%C3%A3o%20importado (Accessed on: Nov 8, 2019)
  56. De OliveiraYTE SternbergE MunhozRFO Formulation for Nasal Solution with Inhibiting Action on the SARS-CoV-2 Virus and Related Pathologies.Patent WO2022226614A12021
     [Google Scholar]
  57. Medication registration. Anvisa approves new generic for the treatment of hepatitis C.Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2018/anvisa-aprova-novo-generico-para-tratamento-da-hepatite-c (Accessed on: Jul 4, 2022).
  58. Ministry of HealthBrazil. Painel Coronavirus.Available from: https://covid.saude.gov.br/ (Accessed on: Jan 6, 2024).
     [Google Scholar]
/content/journals/biot/10.2174/0118722083303431240528041945
Loading
Open Innovation or Traditional Patenting Strategies to Efficiently Address Health Emergencies: How Patent Information was used Towards Effective Treatments for COVID-19
Recent Pat. Biotechnol. 19, 142 (2025); https://doi.org/10.2174/0118722083303431240528041945
/content/journals/biot/10.2174/0118722083303431240528041945
/content/journals/biot/10.2174/0118722083303431240528041945
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): closed innovation; collaboration; COVID-19 drugs; open innovation; Patent mining; treatments

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test